IRIS
VALENTINI, Gabriele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 16.412
NA - Nord America 6.787
AS - Asia 5.075
SA - Sud America 1.188
AF - Africa 61
Continente sconosciuto - Info sul continente non disponibili 18
OC - Oceania 4
Totale 29.545
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 7.544
US - Stati Uniti d'America 6.620
RU - Federazione Russa 2.659
SG - Singapore 1.879
IE - Irlanda 1.848
CN - Cina 1.136
UA - Ucraina 1.122
BR - Brasile 1.040
HK - Hong Kong 1.008
GB - Regno Unito 840
DE - Germania 611
FR - Francia 565
FI - Finlandia 288
VN - Vietnam 255
SE - Svezia 252
NL - Olanda 229
TR - Turchia 211
GR - Grecia 196
KR - Corea 157
IN - India 146
CA - Canada 111
BE - Belgio 71
JP - Giappone 68
AR - Argentina 52
ES - Italia 47
ID - Indonesia 44
BD - Bangladesh 34
MX - Messico 31
EC - Ecuador 29
IQ - Iraq 28
PL - Polonia 28
CH - Svizzera 27
AT - Austria 26
ZA - Sudafrica 21
CO - Colombia 20
PY - Paraguay 15
PK - Pakistan 13
UZ - Uzbekistan 13
EU - Europa 12
MA - Marocco 11
RO - Romania 11
TH - Thailandia 10
CZ - Repubblica Ceca 9
TW - Taiwan 9
UY - Uruguay 9
VE - Venezuela 9
CL - Cile 8
HR - Croazia 8
HU - Ungheria 8
SA - Arabia Saudita 8
KZ - Kazakistan 6
TN - Tunisia 6
AE - Emirati Arabi Uniti 5
AZ - Azerbaigian 5
BH - Bahrain 5
BY - Bielorussia 5
EG - Egitto 5
IR - Iran 5
KE - Kenya 5
PE - Perù 5
KG - Kirghizistan 4
NP - Nepal 4
PA - Panama 4
XK - ???statistics.table.value.countryCode.XK??? 4
AU - Australia 3
BB - Barbados 3
CR - Costa Rica 3
DZ - Algeria 3
IL - Israele 3
JM - Giamaica 3
JO - Giordania 3
NI - Nicaragua 3
RS - Serbia 3
TT - Trinidad e Tobago 3
AL - Albania 2
AP - ???statistics.table.value.countryCode.AP??? 2
DK - Danimarca 2
ET - Etiopia 2
HN - Honduras 2
LB - Libano 2
LT - Lituania 2
MK - Macedonia 2
MY - Malesia 2
NO - Norvegia 2
PH - Filippine 2
PT - Portogallo 2
SN - Senegal 2
SY - Repubblica araba siriana 2
AO - Angola 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BW - Botswana 1
BZ - Belize 1
CG - Congo 1
CI - Costa d'Avorio 1
DO - Repubblica Dominicana 1
GE - Georgia 1
GT - Guatemala 1
KI - Kiribati 1
Totale 29.534
Salva come PNG Salva come JPEG
Città #
Dublin 1.841
Jacksonville 1.575
Hong Kong 1.005
Moscow 882
Santa Clara 807
Chandler 756
Singapore 557
Rome 507
Milan 414
Princeton 288
Medford 254
Beijing 200
Ashburn 197
Ann Arbor 166
Naples 156
Napoli 156
San Mateo 152
Seoul 152
Boardman 148
Roxbury 148
Wilmington 138
Hefei 126
Bremen 113
Woodbridge 113
Ho Chi Minh City 101
Bengaluru 100
Florence 89
Turin 89
Palermo 86
Cambridge 83
Dallas 71
São Paulo 67
Catania 64
Des Moines 64
Mountain View 64
Brussels 62
Hanoi 61
Bari 59
Caserta 58
The Dalles 55
Bologna 53
Ottawa 52
Padova 50
Nanjing 49
New York 44
Verona 39
Genoa 34
Munich 33
Rio de Janeiro 31
Torino 27
Brasília 26
Helsinki 26
Los Angeles 25
Belo Horizonte 24
Cagliari 24
Taranto 24
Mcallen 23
Pescara 23
Messina 22
Toronto 22
Houston 21
Jinan 21
Nuremberg 21
Redwood City 21
Venice 21
Livorno 20
Brescia 19
Guangzhou 19
Parma 19
Vicenza 19
France 18
Genova 18
Perugia 18
Düsseldorf 17
Kunming 17
London 17
Modena 17
Norwalk 17
Salerno 17
Trieste 17
Changsha 15
Curitiba 15
Gorno 15
Reggio Emilia 15
Auburn Hills 14
Baghdad 14
Reggio Calabria 14
Campinas 13
Falls Church 13
Hebei 13
Salvador 13
Dhaka 12
Guarulhos 12
Montréal 12
Ningbo 12
Ribeirão Preto 12
Shanghai 12
Tashkent 12
Trento 12
Belluno 11
Totale 13.310
Salva come PNG Salva come JPEG
Nome #
ARTRITE PSORIASICA ED INTERSTIZIOPATIA POLMONARE : DESCRIZIONE DI UN CASO CLINICO. 7.855
Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: Results of the EUSTAR group 414
ANTI TNF ALFA IN PAZIENTI AFFETTI DA ARTRITE REUMATOIDE E SPONDILOARTRITI HBV CARRIERS OCCULTI:STUDIO RETROSPETTIVO SULLA SICUREZZA 247
A PILOT STUDY ON LOW-DOSE INTRAVENOUS CICLOPHOSPHAMIDE IN SYSTEMIC SCLEROSIS: EFFICACY, SAFETY AND EFFECTS ON CELLULAR ACTIVATION MARKERS 162
Antinuclear antibodies in first-degree relatives of patients with polymyositis-dermatomyositis: analysis of the relationship with HLA haplotypes 138
Clinical and subclinical atherosclerosis in systemic sclerosis: consequences of previous corticosteroid treatment. 137
Diagnostic issues faced by a rare disease healthcare network during Covid-19 outbreak: data from the Campania Rare Disease Registry 135
Association between a stromal cell-derived factor 1 (SDF-1/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis 132
ANTI-TNFα TREATMENT IS ASSOCIATED WITH INCREASED LIVER STIFFNESS IN HBV OCCULT CARRIER PATIENTS 132
Clinical correlates of human leukocyte antigen-G (HLA-G) in systemic sclerosis. 124
Early systemic sclerosis: Analysis of the disease course in patients with marker autoantibody or capillaroscopic positivity or both. 120
Early Systemic Sclerosis: Marker Autoantibody Positive Patients Have A Faster Pace Of The Disease. 118
Polymorphism of immunoglobulin enhancer element HS1,2A: allele *2 associates with systemic sclerosis. Comparison with HLA-DR and DQ allele frequency 114
[T-lymphocyte subpopulations in the conjunctiva of subjects with secondary Sjogren's syndrome] 114
Alterazione del riempimento ventricolare sinistro nella sclerosi sistemica (SSc): risultati di uno studio Iongitudinale 109
Assessment of intestinal permeability and orocecal transit time in patients with systemic sclerosis 109
[HAQ-DI Italian version in systemic sclerosis]. 108
Adult-onset Still's disease: Evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers 106
[Comparison between auranofin and chloroquine in the therapy of rheumatoid arthritis] 106
CXCL4 in undifferentiated connective tissue disease at risk for systemic sclerosis (SSc) (previously referred to as very early SSc) 105
Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation 102
Association of a functional polymorphism in the matrix metalloproteinase-12 promoter region with systemic sclerosis in an Italian population 101
-238 and +489 TNF-alpha along with TNF-RII gene polymorphisms associate with the diffuse phenotype in patients with Systemic Sclerosis 101
Early systemic sclerosis: marker autoantibodies and videocapillaroscopy patterns are each associated with distinct clinical, functional and cellular activation markers. 101
PREVALENCE OF ANTIBODIES RECOGNAIZING CYCLIC CITRULLINATED PEPTIDE(anti CCP) IN PATIENTS WITH ULCERATIVE COLITIS 100
[Survival and death causes in 251 systemic sclerosis patients from a single Italian center]. 100
ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis-a EUSTAR analysis. 100
ARTHRITIS IS ASSOCIATED WITH PSORIASIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES 99
Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients 99
.ANTI-TNF alfa IN PATIENTS WITH EITHER RHEUMATOID ARTHRITIS OR SPONYLOATHRITIS And CONCURRENT C HEPATITIS:A RETROSPECTIVE RECORD REVIEW ON SAFETY 97
Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features 96
EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research 95
Evidence for peripheral impaired glucose handling in patients with connective tissue diseases 94
Evaluation of cardiac structures and function in systemic sclerosis by Doppler echocardiography 94
Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease 94
Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus 94
Cardiac involvement in rheumatoid arthritis: an echocardiographic study 92
Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): Efficacy of maintenance immunosuppression in responders and non-responders. 92
[Hypocomplementemia in systemic sclerosis]. 92
Prevalence of anti-toxoplasma antibodies in patients with autoimmune diseases. 91
Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: A long-term retrospective cohort study 91
Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database 90
[A comparison between the Simplified Disease Activity Index (SDAI) and the Disease Activity Score (DAS28) as measure of response to treatment in patients undergoing different therapeutic regimens]. 90
Tissue Doppler imaging in systemic sclerosis: A 3-year longitudinal study. 89
A SCLERODERMA PATIENT WITH SWOLLEN AND TENDER JOINTS OF BOTH HANDS 89
A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis 89
Cardiac involvement in undifferentiated connective tissue disease at risk for systemic sclerosis (otherwise referred to as very early-early systemic sclerosis): a TDI study 89
Glucocorticoids in systemic sclerosis: patients' beliefs and treatment adherence. 88
Alterazioni del sistema nervoso autonomo nella Sclerosi Sistemica (SSc). Risultati preliminari di uno studio sul rapporto con la severita della malattia 88
Early Systemic Sclerosis: Serum Profiling of Factors Involved in Endothelial, T-cell, and Fibroblast Interplay is Marked by Elevated Interleukin-33 Levels. 88
Systemic sclerosis could mask the presentation of psoriasis in a patient with symptomatic and bilateral sacroiliitis 88
[FRI0313] CYCLOPHOSPHAMIDE PULSE THERAPY IN THE TREATMENT OF SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE G. Abignano, M. Iudici, A. Petrillo, G. Cuomo, G. Valentini. Rheumatology Unit, Second University of Naples, Napoli, Italy Background: Cyclophosphamide (CYC) is currently used in the treatment of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). A recent meta-analysis1 (Nannini C et al), pooling data from studies based on different entry criteria, questions its usefulness. Objectives: To investigate the effectiveness of low dose pulse CYC (500 mg/dose) in the treatment of recently deteriorating SSc-ILD. Methods: 51 patients with SSc-ILD, all of them satisfying ACR criteria for the classification of the disease and presenting with a recent (<6 months) decrease (≥10% of the predictive value) of either Forced Vital Capacity (FVC) or Diffusing Lung Capacity for CO (DLCO), were enrolled in the study. All of them underwent a concurrent prednisone therapy (10 mg/daily). CYC was administered i.v. at a dose of 500 mg weekly. Total CYC dose ranged from 4.5 to 11.5 g (median 7.5). An increase of 10% in either FVC or DLCO was considered indicative of improvement; a change between <10% and >10% of stable disease; a decrease ≥10% of worsening. Results: 22 out of the 51 SSc patients (43.14%) resulted to improve at the end of the CYC course; 17 (33.33%) remained stable; 12 (23.53%) worsened. No patients withdrew CYC treatment because of side effects. Conclusion: Our study suggests that the effectiveness of CYC in SSc-ILD may depend on entry criteria. Actually about 76% of patients who had experienced a recent deterioration of lung function, suggesting active alveolitis, underwent improvement or stabilization of their disease in our study. References:[ol][li]Nannini C, West CP, Erwin PJ, Matteson EL. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 2008, 10:R124.[/li][/ol]Disclosure of Interest: None declared Ann Rheum Dis 2009;68(Suppl3):460 Session: Scleroderma, myositis and related syndromes 88
Cell-free DNA in the plasma of patients with systemic sclerosis 87
Non-Hodgkin's lymphoma in systemic sclerosis: case and literature review 87
[Eosinophilic fasciitis. A recently reported oligotopic connective tissue inflammation. A case report] 87
ANTI-TOPOISOMERASE I (ANTI-SCL-70) AND CANCER IN SYSTEMIC SCLEROSIS. ARE THEY RELATED? 87
RELATIONSHIP OF THE 6-MIN WALKING TEST AND QUALITY OF LIFE 87
The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: Derivation and validation of a preliminarily revised EUSTAR activity index 87
[Italian consensus on the recommendations about the use of methotrexate for the treatment of rheumatic diseases with a focus on rheumatoid arthritis: results from the "3E initiative"]. 86
Effects and safety of rituximab in systemic sclerosis: An analysis from the European Scleroderma Trial and Research (EUSTAR) group 86
Diastolic abnormalities in systemic sclerosis: evidence for associated defective cardiac functional reserve 86
Glucocorticoids in systemic sclerosis: weighing the benefits and risks - a systematic review 86
ATHEROSCLEROSIS AND RHEUMATOID ARTHRITIS: EVALUATION OF INTIMA-MEDIA THICKNESS AND CORRELATION WITH INFLAMMATORY AND ATHEROGENIC MARKERS 86
ELF Score: A Validated Serum Test Strongly Predictive of Fibrosis in Systemic Sclerosis. 86
Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group 85
Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients 85
Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: Results of an Italian observational study 85
RELAPSING POLYCHONDRITIS. AN HYSTOCHEMICAL STUDY BY LECTIN. 84
[Atherosclerosis and rheumatoid arthritis: relationships between intima-media thickness of the common carotid arteries and disease activity and disability]. 84
Sub-Analysis of ELF Score Biomarkers Components Indicates a Specific Correlation with Different Organ Involvement in Systemic Sclerosis. 84
New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors: A systematic analysis. 83
Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study 83
High IL-17E and Low IL-17C Dermal Expression Identifies a Fibrosis-Specific Motif Common to Morphea and Systemic Sclerosis. 83
Impaired exercise performance in systemic sclerosis and its clinical correlations 83
Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy 83
[Metabolic syndrome in inflammatory rheumatic diseases]. 83
VALIDATION OF THE SIMPLIFIED DISEASE ACTIVITY INDEX (SDAI) AND DAS28 AS MEASURE OF RESPONSE TO TREATMENT IN PATIENTS UNDERGOING DIFFERENT THERAPEUTIC REGIMENS 83
[Epidemiology and risk factors in osteoarthritis: literature review data from "OASIS" study]. 82
The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy 82
Osteopenia in systemic sclerosis. Evidence of a participating role of earlier menopause 82
Crioglobulinemia mista essenziale: prevalenza e caratteri della neuropatia periferica 82
European Scleroderma Study Group (ESCSG) Activity Index is correlated to quality of life measures both at admission and overtime 82
Brief report: Successful pregnancies but a higher risk of preterm births in systemic sclerosis: An Italian multicentric study. 82
Anti-centromere protein A antibodies in systemic sclerosis: Significance and origin 82
Low-dose aspirin as primary prophylaxis for cardiovascular events in rheumatoid arthritis: an Italian multicentre retrospective study 82
[Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs]. 81
[Absolute and relative increase in Leu-11b+ cells in patients with systemic scleroderma] 81
Pulmonary hypertension in systemic sclerosis: relationship to other findings of lung involvement 81
Anti-carbamylated protein antibodies and skin involvement in patients with systemic sclerosis: An intriguing association 81
Peripheral T lymphocytes from patients with early systemic sclerosis co-cultured with autologous fibroblasts undergo an oligoclonal expansion similar to that occurring in the skin 80
Succesfull neridronate therapy in transient osteoporosis of the hip 80
Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries 79
Association of the CD226 Ser(307) variant with systemic sclerosis: evidence of a contribution of costimulation pathways in systemic sclerosis pathogenesis 79
Increased expression of CD40 ligand in activated CD4+ T lymphocytes of systemic sclerosis patients 79
Quality of life as measured by the short-form 36 (SF-36) questionnaire in patients with early systemic sclerosis and undifferentiated connective tissue disease. 79
Right atrial morphology and function in patients with systemic sclerosis compared to healthy controls: a two-dimensional strain study 79
Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis 78
Correlations of Y chromosome microchimerism with disease activity in patients with SLE: analysis of preliminary data 78
The incidence of cardiovascular events in Italian patients with systemic lupus erythematosus is lower than in North European and American cohorts: Implication of disease-associated and traditional risk factors as emerged by a 16-year retrospective GIRRCS study 78
Macrophage Activation Syndrome in Patients Affected by Adult-onset Still Disease: Analysis of Survival Rates and Predictive Factors in the Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale Cohort 78
Totale 17.559
Salva come PNG Salva come JPEG
Categoria #
all - tutte 101.834
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 101.834
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.767 0 0 0 0 0 111 381 316 137 363 312 147
2021/20222.634 245 77 93 103 738 103 106 162 134 120 201 552
2022/20234.527 430 195 113 303 394 316 112 297 1.767 184 204 212
2023/20242.785 195 131 182 285 626 109 189 230 130 161 228 319
2024/20255.492 125 162 120 195 715 859 820 459 612 803 381 241
2025/20266.259 526 591 852 893 1.372 2.025 0 0 0 0 0 0
Totale 30.142